Premium
Danon disease: Further clinical and molecular heterogeneity
Author(s) -
Sabourdy Frédérique,
Michelakakis Helen,
Anastasakis Aris,
Garcia Virginie,
Mavridou Irene,
Nieto Michèle,
Pons MarieClaude,
Skiadas Constantinos,
Moraitou Marina,
Manta Panagiota,
Elleder Milan,
Levade Thierry
Publication year - 2009
Publication title -
muscle and nerve
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.025
H-Index - 145
eISSN - 1097-4598
pISSN - 0148-639X
DOI - 10.1002/mus.21252
Subject(s) - proband , subclinical infection , cardiomyopathy , disease , medicine , immunostaining , heart failure , mutation , heart disease , cardiology , pathology , genetics , gene , biology , immunohistochemistry
Abstract Two families of Greek patients with subclinical to severe cardiomyopathy are presented. The diagnosis of Danon disease was supported by a total lack of LAMP2 immunostaining in cultured skin fibroblasts and muscle biopsies. The LAMP2 mutation carried by one patient (c.928G>A) has already been reported but with different symptoms. The second patient had a novel point deletion. This has not been described previously, but it could be detected easily by restriction analysis. This mutation was also found in the patient's brother, and it was associated with severe cardiomyopathy leading to heart failure. Surprisingly, the proband also had partial reduction of α‐galactosidase A activity, despite the absence of characteristic clinical features of Fabry disease. A substitution in the GLA gene (c.937G>T) was found, and its involvement in the cardiac disease is discussed. Muscle Nerve, 2009